We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

UBSG:SIXUBS Group AG Analysis

Data as of 2026-05-16 - not real-time

CHF 35.97

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

UBS Group AG trades at CHF 35.97, comfortably above its 20‑day (CHF 34.29) and 50‑day (CHF 32.09) simple moving averages, indicating short‑term strength, while the MACD histogram remains positive and the signal line is bullish. However, the RSI sits at 68.5, edging toward overbought territory, and the price is flirting with the near‑term resistance around CHF 36.42, suggesting a possible pull‑back before the next leg up.
Fundamentally, the stock’s forward P/E of 11.3 versus a trailing P/E of 16.5 places it at a modest discount to its industry average (16.48), and a dividend yield of 2.4% with a 32% payout ratio points to sustainable income. The latest quarterly reports show a 17% return on CET1 capital and a strong net profit, reinforcing earnings momentum. Yet, regulatory headlines flag heightened capital‑requirement scrutiny in Switzerland, which could pressure balance‑sheet management. With a low beta (0.26) and a 30‑day volatility of 27%, the stock offers relative stability but remains sensitive to macro‑policy shifts. Overall, the setup suggests a fair‑valued, dividend‑supportive stock with short‑term price‑action caution and longer‑term upside potential.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 7/10

Key Factors

  • Price near resistance at CHF 36.42
  • RSI approaching overbought levels
  • Technical bullishness but limited upside in immediate term

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Forward P/E of 11.3 indicating valuation upside
  • Sustainable dividend yield of 2.4%
  • Strong Q1 earnings and CET1 return

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Stable low‑beta profile and solid capital base
  • Consistent profitability and cash generation
  • Potential for earnings growth despite regulatory headwinds

Key Metrics & Analysis

Financial Health

Revenue Growth13.80%
Profit Margin17.76%
P/E Ratio16.5
ROE10.16%
ROA0.57%
P/B Ratio1.6
Industry P/E16.5

Technical Analysis

TrendNeutral
RSI68.5
SupportCHF 32.12
ResistanceCHF 36.42
MA 20CHF 34.29
MA 50CHF 32.09
MA 200CHF 32.72
MACDBullish
VolumeStable
Fear & Greed Index88.52

Valuation

Target PriceCHF 38.95
Upside/Downside8.29%
GradeFair
TypeBlend
Dividend Yield2.40%

Risk Assessment

Beta0.26
Volatility26.97%
Sector RiskLow
Reg. RiskHigh
Geo RiskLow
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.